<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00478101</url>
  </required_header>
  <id_info>
    <org_study_id>GMO-SC-61</org_study_id>
    <nct_id>NCT00478101</nct_id>
  </id_info>
  <brief_title>Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gachon University Gil Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For cancer patients with inadequate pain relief, a switch to an alternative opioid is the&#xD;
      preferred option for symptomatic improvement. However, multiple opioids are often&#xD;
      simultaneously administered for anecdotal reasons.&#xD;
&#xD;
      The present study isdesigned to assess the analgesic profiles of two different strategies in&#xD;
      chronic cancer pain: the opioid rotation from oxycodone to transdermal fentanyl and the&#xD;
      combination of oral oxycodone and transdermal fentanyl.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with uncontrolled cancer pain despite treatment of oral morphine equivalent â‰¥100&#xD;
      mg/d will be randomly assigned to oral opioids to transdermal fentanyl (rotation group) or&#xD;
      oral oxycodone plus fentanyl (combination group). Patients answer a questionnaire that&#xD;
      included pain severity (0 to 10) and interference items at baseline and after one week.&#xD;
      Primary outcomes are change in pain score and treatment success.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain score and treatment success</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
  </secondary_outcome>
  <enrollment type="Actual">2006</enrollment>
  <condition>Advanced Solid Cancers</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxycodone fentanyl</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic Uncontrolled Pain That Required Stronger Opioid Therapy Than They Have Been&#xD;
             Taking&#xD;
&#xD;
          -  Histologically Confirmed Solid Cancer&#xD;
&#xD;
          -  Aged Over 18 Years&#xD;
&#xD;
          -  Admitted in a Palliative Cancer Care Unit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uspected to Have Narcotic Abuse, Clinically Relevant CO2 Retention or Had an Active&#xD;
             Skin Disease&#xD;
&#xD;
          -  Inability to swallow oral medication, and impaired sensory or cognitive function&#xD;
&#xD;
          -  Patients who had an active infection, uncontrolled central nervous system involvement,&#xD;
             or on antitumor therapy of any kind&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Se Hoon Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center, Incheon, Korea</affiliation>
  </overall_official>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>May 22, 2007</study_first_submitted>
  <study_first_submitted_qc>May 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2007</study_first_posted>
  <last_update_submitted>March 12, 2008</last_update_submitted>
  <last_update_submitted_qc>March 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2008</last_update_posted>
  <keyword>Pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

